Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer.

MLA

Caram, Megan E. V., et al. “Survival by First-Line Therapy and Prognostic Group among Men with Metastatic Castration-Resistant Prostate Cancer.” Cancer Medicine, vol. 13, no. 12, June 2024, p. e7334. EBSCOhost, https://doi.org/10.1002/cam4.7334.

APA

Caram, M. E. V., Kumbier, K., Tsao, P. A., Burns, J., Sparks, J. B., Stensland, K. D., Reichert, Z. R., Alumkal, J. J., Hollenbeck, B. K., Shahinian, V., Tsodikov, A., & Skolarus, T. A. (2024). Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Medicine, 13(12), e7334. https://doi.org/10.1002/cam4.7334

Chicago

Caram, Megan E V, Kyle Kumbier, Phoebe A Tsao, Jennifer Burns, Jordan B Sparks, Kristian D Stensland, Zachery R Reichert, et al. 2024. “Survival by First-Line Therapy and Prognostic Group among Men with Metastatic Castration-Resistant Prostate Cancer.” Cancer Medicine 13 (12): e7334. doi:10.1002/cam4.7334.